Ignite Creation Date:
2024-05-06 @ 8:27 PM
Last Modification Date:
2024-10-26 @ 3:28 PM
Study NCT ID:
NCT06386679
Status:
ENROLLING_BY_INVITATION
Last Update Posted:
2024-04-26
First Post:
2024-03-29
Brief Title:
Amniotic Fluid Mesenchymal Stem Cells Developed for Chondrogenic Treatment AFCC Injection in Elderly Knee Osteoarthritis Patients
Sponsor:
Siriraj Hospital
Organization:
Siriraj Hospital
Study Overview
Official Title:
A Pilot Study Safety and Efficacy of Allogenic Mesenchymal Stem Cell Type AFCC for Treating in Elderly Knee Osteoarthritis Patients
Status:
ENROLLING_BY_INVITATION
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Amniotic fluid mesenchymal stem cells developed for chondrogenic treatment AFCC are used to treat elderly patients suffering from knee osteoarthritis OA The injection reduces inflammation and promotes the recovery of knee function leading to an improved quality of life
Detailed Description:
Ten patients aged between 60 and 80 of both genders who were diagnosed with knee osteoarthritis at Kellgren and Lawrence KL score 2-3 were selected based on strict inclusion and exclusion criteria Each patient was treated with a single intra-articular injection of 20 million cells of amniotic fluid mesenchymal stem cells in AFCC type into an OA knee After the treatment they were monitored through clinical assessment and laboratory investigation including blood chemistry test and Magnetic Resonance Imaging MRI of the treated knee
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None